Cellino Biotech, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing autologous induced pluripotent stem cell (iPSC)-derived cell therapies for degenerative diseases. The company's lead program targets Parkinson's disease using patient-derived dopamine neurons[1].
Founded in 2017, Cellino's platform enables the manufacture of personalized cell therapies that avoid immune rejection. The company combines advances in stem cell biology with proprietary manufacturing technologies to create scalable cell replacement therapies[2].
| Program | Cell Type | Indication | Phase | Status |
|---|---|---|---|---|
| CLNO-001 | Autologous iPSC dopamine neurons | Parkinson's Disease | Preclinical | Research |
| Program 2 | iPSC-derived cells | CNS disorder | Discovery | Research |
| Program 3 | iPSC-derived cells | Degenerative disease | Discovery | Research |
CLNO-001 is an autologous iPSC-derived dopamine neuron therapy for Parkinson's disease. The therapy uses the patient's own cells to replace the dopaminergic neurons lost in PD[3].
Mechanism of Action:
Approach:
| Step | Description |
|---|---|
| Cell collection | Patient blood/skin sample |
| iPSC generation | Reprogramming to pluripotent state |
| Differentiation | Directed to dopamine neurons |
| Quality control | Purity, potency, safety |
| Implantation | Stereotactic surgery |
Advantages:
Development Status:
Cellino has developed a comprehensive iPSC platform:
| Component | Description |
|---|---|
| Reprogramming | Non-integrative methods |
| Differentiation | Scalable protocols |
| Banking | Master cell banks |
| Manufacturing | Closed, automated systems |
| Quality control | Potency assays |
The company has invested in scalable manufacturing:
Cellino is developing additional programs:
Induced pluripotent stem cells offer advantages:
PD is an ideal target for cell therapy:
| Partner | Focus Area | Status |
|---|---|---|
| Academic collaborators | Research | Multiple |
| Manufacturing partners | Scale-up | Active |
| Patient foundations | Clinical development | Active |
Cellino maintains IP in key areas:
Cell Therapy
Dopaminergic Neurons
Stem Cell Therapy
BlueRock Therapeutics
Aspen Neuroscience